In order to examine the effectiveness of moxibustion and Goshajinkigan for diabetes we investigated using Otsuka Long-Evans Tokushima Fatty (OLETF) rats and Long-Evans Tokushima Otsuka (LETO) rats. 18 male OLETF rats (5 weeks old) and 6 male LETO rats (5 weeks old) were divided into 4 groups. Group I rats were given trial moxibustion (BL 20, BL 23). Group II rats were administered Goshajinkigan (100mg/kg). Group III (OLETF) and IV (OLETF) rats were untreated as controls. In each group, we measured body weight (BW), blood sugar (BS), urine albumin (UA), pain-related time (PRT) and blood flow volume (BFV) before and after the experiment. Moreover, kidney and pancreas tissues were observed.
In groups I, II and III, BW, BS and UA increased in comparison with that of group IV, as the rats grew older. But groups I and II showed suppressed increases, in comparison with that of III group. After stimulation groups I and II showed reaction sensitivity, in comparison with group III. Group I showed a suppressed decrease of BFV. Tissue samples showed no serious change.
These findings suggest that moxibustion and Goshajinkigan inhibited some quantity of the progress of diabetic disease.

The first examination of the new board of the Japanese cardiovascular surgery took place in 2022. As it is a transitional period for the new system, many doctors are not familiar with the changes and details of the new system, and some have their concerns. Here, we held a round-table discussion with doctors who actually took the new board of the Japanese cardiovascular surgery under the new system, and we summarized their opinion.